These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25151504)

  • 21. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
    Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
    Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics.
    Choi Y; Ahn KJ; Nam Y; Jang J; Shin NY; Choi HS; Jung SL; Kim BS
    Eur J Radiol; 2019 Nov; 120():108642. PubMed ID: 31546124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms.
    Mazurowski MA; Grimm LJ; Zhang J; Marcom PK; Yoon SC; Kim C; Ghate SV; Johnson KS
    Eur J Radiol; 2015 Nov; 84(11):2117-22. PubMed ID: 26210095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying spatial imaging biomarkers of glioblastoma multiforme for survival group prediction.
    Zhou M; Chaudhury B; Hall LO; Goldgof DB; Gillies RJ; Gatenby RA
    J Magn Reson Imaging; 2017 Jul; 46(1):115-123. PubMed ID: 27678245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma.
    Beig N; Bera K; Prasanna P; Antunes J; Correa R; Singh S; Saeed Bamashmos A; Ismail M; Braman N; Verma R; Hill VB; Statsevych V; Ahluwalia MS; Varadan V; Madabhushi A; Tiwari P
    Clin Cancer Res; 2020 Apr; 26(8):1866-1876. PubMed ID: 32079590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
    Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
    Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication.
    Zhou J; Reddy MV; Wilson BKJ; Blair DA; Taha A; Frampton CM; Eiholzer RA; Gan PYC; Ziad F; Thotathil Z; Kirs S; Hung NA; Royds JA; Slatter TL
    AJNR Am J Neuroradiol; 2018 Feb; 39(2):252-259. PubMed ID: 29191871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-parametric (ADC/PWI/T2-w) image fusion approach for accurate semi-automatic segmentation of tumorous regions in glioblastoma multiforme.
    Fathi Kazerooni A; Mohseni M; Rezaei S; Bakhshandehpour G; Saligheh Rad H
    MAGMA; 2015 Feb; 28(1):13-22. PubMed ID: 24691860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
    Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
    Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation between pilocytic astrocytoma and glioblastoma: a decision tree model using contrast-enhanced magnetic resonance imaging-derived quantitative radiomic features.
    Dong F; Li Q; Xu D; Xiu W; Zeng Q; Zhu X; Xu F; Jiang B; Zhang M
    Eur Radiol; 2019 Aug; 29(8):3968-3975. PubMed ID: 30421019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracted magnetic resonance texture features discriminate between phenotypes and are associated with overall survival in glioblastoma multiforme patients.
    Chaddad A; Tanougast C
    Med Biol Eng Comput; 2016 Nov; 54(11):1707-1718. PubMed ID: 26960324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival.
    Henker C; Kriesen T; Glass Ä; Schneider B; Piek J
    J Neurooncol; 2017 Nov; 135(2):391-402. PubMed ID: 28755324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation.
    Zhu Y; Young GS; Xue Z; Huang RY; You H; Setayesh K; Hatabu H; Cao F; Wong ST
    Acad Radiol; 2012 Aug; 19(8):977-85. PubMed ID: 22591720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients.
    Peeken JC; Hesse J; Haller B; Kessel KA; Nüsslin F; Combs SE
    Strahlenther Onkol; 2018 Jun; 194(6):580-590. PubMed ID: 29442128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting MGMT methylation status of glioblastomas from MRI texture.
    Levner I; Drabycz S; Roldan G; De Robles P; Cairncross JG; Mitchell R
    Med Image Comput Comput Assist Interv; 2009; 12(Pt 2):522-30. PubMed ID: 20426152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.